Daewoong begins sales of Nuceiva botulinum in Italy

Daewoong Pharmaceutical began sales of its Nabota botulinum toxin in Italy, the Korean pharmaceutical company said Friday.

Daewoong Pharmaceutical's botulinum toxin Nabota, which is marketed under the brand Nuceiva in Europe [DAEWOONG PHARMACEUTICAL]

Daewoong Pharmaceutical began sales of its Nabota botulinum toxin in Italy, the Korean pharmaceutical company said Friday.

The product is exported as Nuceiva in Europe.

Among European countries, Italy is the fourth market that Daewoong’s Nuceiva is entering following the United Kingdom, Germany, and Austria. Italy is the fourth biggest European market for botulinum toxin, according to market tracker Fortune Business Insight.

California-based Evolus, Daewoong's U.S. partner, is handling the sales and distribution of Nabota in Italy in collaboration with GP Dermal Solution, a distributor in the country, according to Daewoong.

Botulinum toxin is popularly known by its brand name Botox. It was developed by Allergan, which was acquired by AbbVie in 2019, and is a substance that paralyzes muscles and is frequently used by surgeons to reduce wrinkles.

Daewoong’s Nabota has so far been approved by regulators in 63 countries and signed export deals in more than 80 countries. It will be available in Singapore, Peru and Chile this year, according to the company.

Nabota obtained U.S. Food and Drug Administration (FDA) approval in 2018, becoming the first Korean botulinum toxin product to enter the U.S. market. It is currently being sold under the brand Jeuveau in the United States.

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]